SEM News & Events

Sees FY25 Adjusted EBITDA $520.0M-$540.0M.

Reports Q1 revenue $1.421B, consensus $1.41B.

Benchmark analyst Bill Sutherland downgraded Select Medical to Hold from Buy with no price target after the company agreed to be acquired by a consortium led by Executive Chairman Bob Ortenzio for $16.50 per share in cash. Given an uneven five-year performance record, the firm expects a majority of shareholders will approve the deal despite a valuation at the lower end of its peer group, the analyst tells investors.

Deutsche Bank downgraded Select Medical to Hold from Buy with a price target of $16.50, up from $16.20, after the company agreed to be acquired by a consortium led by Executive Chairman and Co-founder Bob Ortenzio for $16.50 per share.